本文由小咖机器人翻译整理

期刊来源：Ann Intern Med

原文链接：https://doi.org/10.7326/AITC202402200

摘要内容如下：

免疫相关不良事件（IRAEs）是在癌症患者中给予靶向免疫检查点的单克隆抗体（免疫检查点抑制剂[ICIs]）后出现的毒性。它们可以在ICI治疗开始后的任何时间发生，具有广泛的临床表型，可以是器官特异性的或全身性的。虽然大多数IRAE表现为轻度至中度的体征和症状，但严重的IRAE可导致不可逆的器官衰竭，并出现危及生命的急性表现。治疗应根据所涉及的具体器官和严重程度进行调整。糖皮质激素是大多数IRAE的一线治疗药物，免疫抑制剂和生物制剂主要用于二线治疗。

英文原文如下：

Abstracts

Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time after initiation of ICI treatment, with a broad clinical phenotype that can be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms of irAEs can lead to irreversible organ failure and have acute life-threatening presentations. Treatment should be tailored to the specific organ involved and the severity. Glucocorticoids are the first-line treatment for most irAEs, with immunosuppressants and biologics mainly used as second-line treatments.

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。

现在购买可享受最大优惠（买一年送三个月，买两年送一年），2024年2月10日起将不再享有该优惠。